Eli Lilly | LLY - Equity Capital And Reserves


Eli Lilly reported $33.88B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Abbott USD 52.06B 69M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Baxter International USD 6.21B 163M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Drreddys Laboratories INR 380.46B 376.31B Mar/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
J&J USD 84.97B 3.78B Jun/2026
Medtronic USD 50.07B 1.09B Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Perrigo USD 2.52B 17M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 1.92B 29.2M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Sanofi EUR 73.14B 1.43B Mar/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Zoetis USD 3.15B 85M Jun/2026